Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05914090
Other study ID # 2023--1968
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 11, 2023
Est. completion date December 30, 2024

Study information

Verified date October 2023
Source Chinese Academy of Medical Sciences, Fuwai Hospital
Contact Yan/Principle investigator
Phone 13641158173
Email yanfuxia@sina.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Among adults, patients undergoing elective extracorporeal circulation for cardiac surgery are included in the ERAS strategy intervention plan, which mainly includes preoperative education, preoperative oral intake of multidimensional carbohydrate beverages, multimodal analgesia, blood protection strategies, correction of perioperative hypoalbuminemia, early removal of tracheal intubation, maintenance of blood sugar at reasonable levels, and targeted liquid therapy. The traditional plan group follows the current clinical diagnosis and treatment routine. By comparing the differences in the incidence of major postoperative outcomes (MACCE events, major pulmonary complications, and acute kidney injury) between the intervention group and the non intervention group, as well as comparing other adverse events (including but not limited to pneumonia, massive bleeding, postoperative arrhythmia, incision infection, postoperative nausea, vomiting, and delirium), all cause secondary intubation, and all cause secondary surgery between the two groups, and recording hospitalization time, ICU stay time The removal time of tracheal intubation and drainage tube, as well as the pain score during hospitalization and the total amount of opioid drug use (converted to equivalent dose morphine), hospitalization cost, postoperative recovery quality QoR15 scale score, and patient satisfaction score, were recorded to explore whether the ERAS regimen can reduce the incidence of major postoperative adverse events, improve patient prognosis, and accelerate postoperative recovery compared to traditional regimens.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 3600
Est. completion date December 30, 2024
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Patients aged 18 to 80 years - Patients awaiting elective cardiac surgery with cardiopulmonary bypass (CPB) Exclusion Criteria: - American Society of Anesthesiologists (ASA) class is above class V - Patients with cardiac assist device or mechanical ventilation - The ejection fraction of patients is less than 30% - Patients with morbid obesity - Patients with severe obstructive sleep apnea-hypopnea syndrome (OSAHS) - Patients with severe pulmonary disease, including severe chronic obstructive pulmonary disease (COPD) or respiratory failure - Patients with severe liver or renal dysfunction, including severe acute or chronic renal dysfunction need renal replacement therapy, and acute or chronic liver failure need artificial liver therapy - Patients with long-term opioid or sedative utilization - Patients with a history of alcohol or cigarette abuse - Patients with long-term hormone therapy - An international normalized ratio > 2.0 - Patients with severe malnutrition - Mental or legal disability - Current enrollment in another clinical trial - Patients' refusal or low adherence

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
ERAS
Among adults, patients undergoing elective extracorporeal circulation for cardiac surgery are included in the ERAS strategy intervention plan, which mainly includes preoperative education, preoperative oral intake of multidimensional carbohydrate beverages, multimodal analgesia, blood protection strategies, correction of perioperative hypoalbuminemia, early removal of tracheal intubation, maintenance of blood sugar at reasonable levels, and targeted liquid therapy.

Locations

Country Name City State
China Fuwai hospital China Beijing
China Fuwai hospital China Beijing

Sponsors (1)

Lead Sponsor Collaborator
Yan Fuxia

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Composite outcomes The composite outcomes include the major adverse cardiac and cerebrovascular events (MACCE), major postoperative pulmonary complication (PPCs), and acute kidney injury (AKI). during hospitalization, an average of 1 week, assessed up to 30 days
Secondary the quality of recovery score (QoR)-15 after surgery At 24 hour after surgery
Secondary length of hospital stay From the date of admission until the date of discharging From the date of admission until the date of discharging, assessed up to 30 days
Secondary the duration of intensive care unit (ICU) stay Time from ICU admission to ICU discharge Time from ICU admission to ICU discharge, assessed up to 30 days
Secondary time to extubation The time from the end of operation to the removal of tracheal intubation The time from the end of operation to the removal of tracheal intubation, assessed up to 30 days
Secondary time to drainage removal The time from the end of operation to the removal of drainage tube The time from the end of operation to the removal of drainage tube, assessed up to 30 days
Secondary the rate of other complications The rate of other complications include delium, pneumonia, pneumothorax, hematorrhea and so on during hospitalization, an average of 1 week, assessed up to 30 days
Secondary the rate of reintubation for any cause The rate of reintubation for any cause during hospitalization, an average of 1 week, assessed up to 30 days
Secondary cumulative opioid dosage Total perioperative consumption of opioid analgesics during hospitalization, an average of 1 week, assessed up to 30 days
Secondary overall medical costs Total cost of patients during hospitalization during hospitalization, an average of 1 week, assessed up to 30 days
Secondary satisfaction score A satisfaction rating using a 0-10 number scale (0=unsatisfactory, 10=satisfactory) the day before discharge, assessed up to 30 days
Secondary the outcomes of long-term prognosis by telephone follow-up the outcomes of prognosis within 30 days, 3 months, and 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05054179 - Pecto-Intercostal Fascial Plane Block Catheter Trial for Reduction of Sternal Pain Phase 2/Phase 3
Completed NCT04051021 - Non-Pharmacological Interventions on Patient Experience and Healthcare Utilization in Adult Cardiac Surgery Patients N/A
Recruiting NCT04604886 - The Consistency of Cardiac Output Measured by Pulmonary Artery Catheter and LiDCO in Cardiac Surgical Patients N/A
Recruiting NCT04075981 - Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF) Phase 3
Completed NCT04062396 - Comparison of Remowell 2 and Inspire on Delirium and Cognitive Dysfunction N/A
Recruiting NCT04709705 - DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS) Phase 2/Phase 3
Not yet recruiting NCT05563662 - SURgical Registry of ENDocarditis EuRope
Withdrawn NCT03289104 - Improving Sternal Healing After Cardiac Surgery: Sternal Wire vs ZIPFIX N/A
Completed NCT02964026 - Study of Clinical Outcomes Associated With the Pulmonary Artery Catheter (PAC) in Cardiac Surgery Patients N/A
Completed NCT04199039 - Effects of Endotracheal Tube Fixation Methods on Hemodynamic Parameters During Endotracheal Suction N/A
Completed NCT03563196 - Diagnosis Of Pulmonary Complications After Cardiac Surgery In Children
Completed NCT02471001 - The Levels of Anaesthetics in Heart Muscle During Heart Surgery N/A
Completed NCT02325726 - RRI Compared With NephroCheckTM to Predict Acute Renal Failure After Cardiac Surgery. N/A
Completed NCT01246947 - Tricuspid Annuloplasty for Moderate Tricuspid Regurgitation Associated With Miral Operation N/A
Completed NCT01151254 - Comparison of Propofol Based Versus Volatile Based Anesthesia and Postoperative Sedation N/A
Completed NCT00996099 - Continuous Glucose Monitoring Combined With Computer Algorithm for Intensive Insulin Therapy in Cardiosurgical Patients N/A
Completed NCT00821262 - Sevoflurane in Cardiac Surgery Phase 4
Completed NCT00617955 - Effects of Aprotinin During Cardiac Surgery/Long Term Death Rates N/A
Completed NCT00337805 - Double Blind Randomized Trial of Saline vs Pentaspan for Resuscitation After Cardiac Surgery Phase 2/Phase 3
Completed NCT00336466 - The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS) Phase 2